Introduction Depressive disorder is common in children and adolescents, with important consequences and serious impairments in terms of personal and social functioning. While both pharmacological and psychological interventions have been shown to be effective, there is still uncertainty about the balance between these and what treatment strategy should be preferred in clinical practice. Therefore, we aim to compare and rank in a network meta-analysis (NMA) the commonly used psychological, pharmacological and combined interventions for depressive disorder in children and adolescents.
Methods and analysis We will update the literature search of two previous NMAs for the identification of trials of antidepressant and psychotherapy alone for depressive disorder in children and adolescents. For identification of trials of combination interventions, seven databases (PubMed, EMBASE, CENTRAL (Cochrane Central Register of Controlled Trials), Web of Science, PsycINFO, CINAHL, LiLACS) will be searched from date of inception. We will also search ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform and check relevant reports on the US Food and Drug Administration website for unpublished data. Building on our previous findings in the field, we will include any commonly prescribed oral antidepressants and any manualised or structured psychotherapies, as well as their combinations. Randomised controlled trials assessing any active intervention against active comparator or pill placebo/psychological controls in acute treatment for depressive disorder in children and adolescents will be included. The primary outcomes will be efficacy (mean change in depressive symptoms), and acceptability of treatment (dropout rate due to any cause). The secondary outcomes will be remission rate, tolerability of treatment (dropouts for adverse events), as well as suicide-related outcomes (suicidal behaviour or ideation). We will perform Bayesian NMAs for all relative outcome measures. Subgroup analyses and sensitivity analyses will be conducted to assess the robustness of the findings.
Dissemination This NMA will provide the most up to date and clinically useful information about the comparative efficacy and acceptability of antidepressants, psychological intervention and their combination in the acute treatment of children and adolescents with depressive disorder. This is the newest NMA and therefore these results are very important in terms of evidence-based medicine. The results will be disseminated through peer-reviewed publication.
Protocol registration PROSPERO CRD42015020841.
- network metaDanalysis
- systematic review
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Contributors PX, AC and XZ conceived the study and drafted the protocol. PX, AC and XZ wrote the first draft of the manuscript. PC, SEH, JRW, CDG, TAF, JB, DC, SL, AVR assisted in protocol design and revision. XZ, YZ and LY participated in the search strategy development. CDG and JP participated in the design of data synthesis and analysis. All the authors have approved the publication of the protocol.
Funding This work is supported by the National Basic Research Program of China (973 Program) (Grant No. 2009CB918300).
Disclaimer The funders had no role in the protocol design; the writing of the protocol or the decision to submit the protocol for publication.
Competing interests AC reports personal fees from Accord Healthcare as an expert witness for a patent issue about quetiapine extended release. SEH is an editor of the Cochrane Common Mental Disorders Group, an author of the Cochrane systematic review of newer generation antidepressants for depression in children and adolescents. and an author (senior) on the Cochrane review of psychological, pharmacological and their combination for child/adoles depression. DC reports grants and personal fees from Shire; personal fees from Eli Lilly, Janssen Cilag, Novartis, Sandoz, Oxford University Press and grants from European Union FP7, outside of the submitted work. Eli Lilly has provided drugs for a clinical trial led by SL as the principal investigator. AVR reports personal fees from Bristol Myers Squibb, Pfizer, Sunovion; grants from Pfizer, Grand Challenges Canada, Canadian Institute of Health Research and AstraZeneca, outside of the submitted work. TAF has received lecture fees from Eli Lilly, Janssen, Meiji, MSD, Otsuka, Pfizer and TanabeDMitsubishi and consultancy fees from Sekisui Chemicals and Takeda Science Foundation. He has received royalties from IgakuDShoin and Nihon Bunka KagakuDsha publishers. He has received research support from Mochida and TanabeDMitsubishi. XZ, YZ, PC, JRW, JP, CDG, TAF, JB and LY declare no competing interests.
Patient consent This protocol meta-analysis did not involve patient consent.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement This protocol did not involve unpublished data.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.